Clearside Biomedical, Inc. (CLSD)

1.4500 +0.1200 (+9.02%) At close: 04:00PM EDT

Clearside Biomedical, Inc.

900 North Point Parkway
Suite 200
Alpharetta, GA 30005
United States
678 270 3631
https://clearsidebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 30

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.	President, CEO & Director	836.15k	N/A	1952
Mr. Charles A. Deignan	Chief Financial Officer	568.68k	N/A	1964
Ms. Jenny R. Kobin	Head of Investor Relations	N/A	N/A	1967
Mr. Rick McElheny	Senior Vice President of Corporate Development & Alliance Management	N/A	N/A	N/A
Mr. Rafael V. Andino	Senior Vice President of Engineering & Manufacturing	N/A	N/A	1965
Ms. Susan L. Coultas Ph.D.	Chief Clinical Officer	N/A	N/A	N/A
Dr. Ngai Hang Chong FRCOphth, FRCS, M.B.A., M.D.	Chief Medical Officer	N/A	N/A	N/A
Mr. Leslie B. Zacks	Secretary	N/A	N/A	1969

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.